Electra Therapeutics (NASDAQ:ETRA) Director Carl Gordon Acquires 156,091 Shares of Company Stock

Electra Therapeutics, Inc. (NASDAQ:ETRA) Director Carl Gordon purchased 156,091 shares of the business’s stock in a transaction dated Thursday, November 5th. The shares were acquired at an average price of $7.31 per share, for a total transaction of $1,141,025.21. Following the acquisition, the director owned 5,220,762 shares of the company’s stock, valued at $38,163,770.22. This trade represents a 3.08% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Electra Therapeutics Stock Performance

Shares of Electra Therapeutics stock opened at $7.35 on Friday. Electra Therapeutics, Inc. has a twelve month low of $6.86 and a twelve month high of $15.50.

Analysts Set New Price Targets

Several brokerages have commented on ETRA. TD Cowen started coverage on Electra Therapeutics in a report on Tuesday, October 13th. They set a “buy” rating on the stock. HC Wainwright assumed coverage on Electra Therapeutics in a research report on Monday, October 26th. They issued a “buy” rating and a $30.00 price target on the stock. Jefferies Financial Group started coverage on Electra Therapeutics in a research note on Tuesday, October 13th. They issued a “buy” rating and a $32.00 price target for the company. Evercore assumed coverage on Electra Therapeutics in a research note on Tuesday, October 13th. They issued an “outperform” rating and a $36.00 price target for the company. Finally, JPMorgan Chase & Co. assumed coverage on Electra Therapeutics in a research report on Thursday, October 22nd. They set an “overweight” rating and a $36.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, Electra Therapeutics has an average rating of “Buy” and an average price target of $33.50.

Key Stories Impacting Electra Therapeutics

Here are the key news stories impacting Electra Therapeutics this week:

• Positive Sentiment: Director Carl Gordon, associated with OrbiMed Advisors, reported purchases totaling 472,571 shares across November 3–5, worth approximately $3.6 million. The transactions increased his reported position, a sign of insider confidence. SEC filing
• Neutral Sentiment: Management plans to present at the Jefferies Global Healthcare Conference in London on November 18. The announcement provides an opportunity to discuss the company, but no new clinical or business developments were included. Conference announcement

About Electra Therapeutics

Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function.

Electra’s lead investigational product is ELA026, an antibody targeting SIRPα, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.